GENELUX Corp
GNLX · XNASCIK 1231457fmd_0T40HWR377EXFG9N6PW0PXZ0P6Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2022 to Jun 30, 2026, 18 periods
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total revenues | 11 | 0 | 0 | 0 |
| Research and development | 9 | 13 | 19 | 20 |
| Total operating expenses | 14 | 24 | 32 | 33 |
| Operating income | (3) | (24) | (32) | (33) |
| Interest expense | – | 0 | – | – |
| Interest and investment income | – | 0 | 1 | 1 |
| Other non-operating income (expense) | (1) | (4) | 2 | 1 |
| Income tax expense | 1 | – | – | – |
| Net income | (5) | (28) | (30) | (32) |